scholarly journals Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance

Diabetes Care ◽  
2006 ◽  
Vol 29 (5) ◽  
pp. 1083-1089 ◽  
Author(s):  
L. G. K. de Aguiar ◽  
L. R. Bahia ◽  
N. Villela ◽  
C. Laflor ◽  
F. Sicuro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Glucose Tolerance ◽  
Vascular Reactivity ◽  
Normal Glucose Tolerance ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
First Degree Relatives ◽  
Normal Glucose ◽  
Type 2 Diabetic

scholarly journals Inflammation, Insulin Resistance, and Glucose Intolerance in Acute Myocardial Infarction Patients without a Previous Diagnosis of Diabetes Mellitus

2005 ◽  
Vol 90 (1) ◽  
pp. 175-180 ◽  
Author(s):  
K. M. Choi ◽  
K. W. Lee ◽  
S. G. Kim ◽  
N. H. Kim ◽  
C. G. Park ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Normal Glucose Tolerance ◽  
Serum Adiponectin ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Reactive Protein ◽  
Previous Diagnosis ◽  
Normal Glucose ◽  
Type 2 Diabetic

Abstract We examined the prevalence of impaired glucose metabolism and its association with inflammation and insulin resistance (IR) in acute myocardial infarction (AMI) patients without a previous diagnosis of diabetes. This prospective study enrolled 52 AMI patients, and 75-g oral glucose tolerance testing was performed on 30 patients at discharge and again 3 months later. We also measured serum adiponectin, high sensitive C-reactive protein, and IL-6 on both occasions. Data were compared with those of 30 type 2 diabetic patients without a history of AMI. Forty percent and 36.7% of AMI patients had impaired glucose tolerance (IGT) at discharge and at 3 months, respectively. The corresponding proportions for newly diagnosed diabetes are 33.0% and 30.0%. At discharge, AMI patients with IGT or diabetes showed higher high sensitive C-reactive protein and IL-6 levels compared with AMI patients with normal glucose tolerance or control type 2 diabetic patients. Furthermore, AMI patients with IGT or diabetes exhibited higher IR and lower serum adiponectin levels than AMI patients with normal glucose tolerance at 3 months after discharge. Previously undiagnosed diabetes and IGT are common in Korean patients with AMI. These glycometabolic abnormalities are associated with inflammation, IR, and serum adiponectin levels.

scholarly journals Impact of Metabolic Syndrome Risk Factors in First-Degree Relatives of Type 2 Diabetic Patients

2007 ◽  
Vol 4 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Susana Siewert ◽  
Sergio Filipuzzi ◽  
Leticia Codazzi ◽  
Irma Gonzalez ◽  
Marta S. Ojeda
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
First Degree Relatives ◽  
Type 2 Diabetic

scholarly journals Low-Dose Acrolein, an Endogenous and Exogenous Toxic Molecule, Inhibits Glucose Transport via an Inhibition of Akt-Regulated GLUT4 Signaling in Skeletal Muscle Cells

2021 ◽  
Vol 22 (13) ◽  
pp. 7228
Author(s):  
Ching-Chia Wang ◽  
Huang-Jen Chen ◽  
Ding-Cheng Chan ◽  
Chen-Yuan Chiu ◽  
Shing-Hwa Liu ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Glucose Metabolism ◽  
Glucose Tolerance ◽  
Protein Expression ◽  
Glucose Uptake ◽  
Glucose Transport ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Urinary acrolein adduct levels have been reported to be increased in both habitual smokers and type-2 diabetic patients. The impairment of glucose transport in skeletal muscles is a major factor responsible for glucose uptake reduction in type-2 diabetic patients. The effect of acrolein on glucose metabolism in skeletal muscle remains unclear. Here, we investigated whether acrolein affects muscular glucose metabolism in vitro and glucose tolerance in vivo. Exposure of mice to acrolein (2.5 and 5 mg/kg/day) for 4 weeks substantially increased fasting blood glucose and impaired glucose tolerance. The glucose transporter-4 (GLUT4) protein expression was significantly decreased in soleus muscles of acrolein-treated mice. The glucose uptake was significantly decreased in differentiated C2C12 myotubes treated with a non-cytotoxic dose of acrolein (1 μM) for 24 and 72 h. Acrolein (0.5–2 μM) also significantly decreased the GLUT4 expression in myotubes. Acrolein suppressed the phosphorylation of glucose metabolic signals IRS1, Akt, mTOR, p70S6K, and GSK3α/β. Over-expression of constitutive activation of Akt reversed the inhibitory effects of acrolein on GLUT4 protein expression and glucose uptake in myotubes. These results suggest that acrolein at doses relevant to human exposure dysregulates glucose metabolism in skeletal muscle cells and impairs glucose tolerance in mice.

Sign in / Sign up

Export Citation Format

Share Document